[go: up one dir, main page]

MXPA05013692A - Metodos para tratar trastornos por acumulacion de proteina. - Google Patents

Metodos para tratar trastornos por acumulacion de proteina.

Info

Publication number
MXPA05013692A
MXPA05013692A MXPA05013692A MXPA05013692A MXPA05013692A MX PA05013692 A MXPA05013692 A MX PA05013692A MX PA05013692 A MXPA05013692 A MX PA05013692A MX PA05013692 A MXPA05013692 A MX PA05013692A MX PA05013692 A MXPA05013692 A MX PA05013692A
Authority
MX
Mexico
Prior art keywords
therapeutic agents
protein
treatment
protein aggregation
inclusions
Prior art date
Application number
MXPA05013692A
Other languages
English (en)
Inventor
Richard Mclaughlin
Original Assignee
Neurochem Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem Int Ltd filed Critical Neurochem Int Ltd
Publication of MXPA05013692A publication Critical patent/MXPA05013692A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

La presente invencion se basa, al menos en parte en el descubrimiento de los agentes terapeuticos capaces de prevenir, inhibir o modular procesamiento anormal, mal plegamiento o agregacion de proteinas. Los agentes terapeuticos de la invencion pueden prevenir, inhibir o modular la formacion de inclusiones. Los agentes terapeuticos de la invencion pueden ser capaces de facilitar la depuracion y/o bloquear la toxicidad celular de inclusiones para tratar o mejorar trastornos caracterizados por agregacion de proteinas. Los compuestos que se unen a motivos estructurales encontrados comunmente en agregados de proteinas, tales como laminas O, representarian candidatos fuertes para tales compuestos y son por lo tanto deseables.
MXPA05013692A 2003-06-23 2004-06-21 Metodos para tratar trastornos por acumulacion de proteina. MXPA05013692A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48091803P 2003-06-23 2003-06-23
US51201703P 2003-10-17 2003-10-17
US87161304A 2004-06-18 2004-06-18
PCT/IB2004/002405 WO2005000288A2 (en) 2003-06-23 2004-06-21 Treatment of protein aggregation disorders

Publications (1)

Publication Number Publication Date
MXPA05013692A true MXPA05013692A (es) 2006-03-13

Family

ID=33556419

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013692A MXPA05013692A (es) 2003-06-23 2004-06-21 Metodos para tratar trastornos por acumulacion de proteina.

Country Status (7)

Country Link
EP (1) EP1646375A2 (es)
JP (1) JP2007521255A (es)
AU (1) AU2004251511A1 (es)
CA (1) CA2528627A1 (es)
IL (1) IL172249A0 (es)
MX (1) MXPA05013692A (es)
WO (1) WO2005000288A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937239A2 (en) * 2005-09-30 2008-07-02 Neurochem (International) Limited Pharmaceutical compositions comprising carboxyalkylsulfonic acids
EP2047393A1 (en) * 2006-08-04 2009-04-15 Lonza Biologics plc. Method for predicting protein aggregation and designing aggregation inhibitors
CA2723440A1 (en) * 2008-05-05 2009-11-12 Tiltan Pharma Ltd. Sulfobetaines for therapy
ES2581482T3 (es) 2011-05-26 2016-09-06 Jado Technologies Gmbh Derivados de amino y amonio hidroxi-sustituidos y su uso médico
DK2809318T3 (da) 2011-05-26 2019-07-22 Gri Bio Inc Ammoniumholdige sulfonsyre-, phosphonsyre- og carboxylsyrederivater og disses medicinske anvendelse
US9751834B2 (en) 2011-05-26 2017-09-05 Gri Bio, Inc. Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
JP7158420B2 (ja) 2017-02-24 2022-10-21 アルツェオン・インコーポレーテッド 神経変性障害を処置するための方法
CN112912732A (zh) * 2018-08-03 2021-06-04 香港大学 用于淀粉样蛋白原纤维、淀粉样蛋白斑块、rna和核仁的检测和成像的组合物和方法
EP4056175A4 (en) * 2019-11-08 2023-12-06 Central Glass Company, Limited METHOD FOR SELECTIVELY KILLING CELLS CONTAINING PROTEIN AGGREGATES, RELATED KIT, THERAPEUTIC DRUG FOR PROTEIN MISFOLDING DISEASES, AND DRUG PRODUCT FOR REMOVING PROTEIN AGGREGATES FROM BLOOD PRODUCT
CN111500729B (zh) * 2020-05-14 2022-02-01 中国人民解放军总医院 血浆lnc-SCA7在制备判断患者是否对新辅助化疗敏感的生物标志物中的应用
WO2024123100A1 (ko) * 2022-12-09 2024-06-13 경희대학교 산학협력단 신규 아밀로이드-베타 응집체 분해제와 이를 이용한 뇌 표적화 약물 전달 시스템
WO2024220996A2 (en) * 2023-04-21 2024-10-24 Stowers Institute For Medical Research Methods for diagnosing, screening and treating an amyloid-associated condition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2104594C (en) * 1991-02-22 2004-05-11 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
CA2250780A1 (en) * 1996-04-10 1997-10-16 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
DE69842048D1 (de) * 1997-08-01 2011-01-27 Max Planck Gesellschaft Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein-aggregaten
CA2320556A1 (en) * 1999-09-29 2001-03-29 Queen's University At Kingston N,n-dichlorinated omega amino acids and uses thereof
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
US20020155172A1 (en) * 2000-04-07 2002-10-24 Junying Yuan Methods and compounds for decreasing cell toxicity or death
GB0117326D0 (en) * 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
AU2003291910B2 (en) * 2002-12-24 2009-10-01 Bellus Health (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases

Also Published As

Publication number Publication date
JP2007521255A (ja) 2007-08-02
AU2004251511A1 (en) 2005-01-06
WO2005000288A2 (en) 2005-01-06
EP1646375A2 (en) 2006-04-19
CA2528627A1 (en) 2005-01-06
WO2005000288A3 (en) 2005-05-06
IL172249A0 (en) 2006-04-10

Similar Documents

Publication Publication Date Title
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
MXPA05013692A (es) Metodos para tratar trastornos por acumulacion de proteina.
DE69710224D1 (de) Behandlung von neurodegenerativen zuständen mittels nimesulide
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
ATE361067T1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
NO20073099L (no) Amino-imidazoloner for inhibering av beta-sekretase
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
WO2003050122A3 (en) Mitotic kinesin inhibitors
EP1515724A4 (en) MITOTIC KINESINE HEMMER
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
WO2005118511A3 (en) Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
WO2004056315A3 (en) Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
BRPI0519424A2 (pt) composiÇÕes e mÉtodos para tratamento de distérbios de proliferaÇço celular
EA200301232A1 (ru) Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2005065183A3 (en) Mitotic kinesin inhibitors
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
ATE419249T1 (de) Inhibitoren von mitotischem kinesin
TW200503722A (en) Substituted 7-aza-quinazoline compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal